Quantcast
Home > Quotes > IMRNW

Immuron Limited Warrants (IMRNW) Quote & Summary Data

IMRNW 
$2.1899
*  
0.257
10.5%
Get IMRNW Alerts
*Delayed - data as of Nov. 15, 2018  -  Find a broker to begin trading IMRNW now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
$ 2.28 / $ 2.1899
Share Volume
1,142
50 Day Avg. Daily Volume
N/A
Previous Close
$ 2.4469
52 Week High / Low
$ 9.04 / $ 0.90
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
1,142
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $2.1899 is 143.32% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.28 $ 9.04
 Low: $ 2.1899 $ 0.90

Company Description (as filed with the SEC)

We were incorporated under the laws of the Commonwealth of Australia in 1994 and have been listed on the Australian Securities Exchange (ASX) since April 30, 1999. Our principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, Australia 3053 and our telephone number is +61 (0)3 9824 5254. We are a clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies that we believe can address significant unmet medical needs. Our oral polyclonal antibodies offer targeted delivery within the gastrointestinal (GI) track but do not cross into the bloodstream, potentially leading to much improved safety and tolerability, without sacrificing efficacy. We believe that our two lead immunomodulator product candidates, IMM-124E and IMM-529, have the potential to transform the existing treatment paradigms for NASH and for C.  ... More ...  

Nasdaq Official Price

Open Price:
$ 2.28
Open Date:
Nov. 15, 2018
Close Price:
$ 2.19
Close Date:
Nov. 15, 2018

Research Brokers before you trade

Want to trade FX?

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x